Goldman Sachs reiterates Buy on FMC stock after Q1 beat By Investing.com

FMC beat first-quarter expectations with adjusted EBITDA of $72 million versus $50 million consensus, and revenue of $759 million versus $745.2 million expected. Goldman Sachs reiterated a Buy rating and $21 price target, implying about 37% upside from the current $15.38 share price. The main offset is softer Q2 guidance of $130 million to $150 million EBITDA, well below the $177 million consensus, even though full-year 2026 guidance was maintained at $670 million to $730 million.

Analysis

The key signal is not the quarter itself, but the asymmetry between current expectations and the company’s ability to defend the outer year. Management is effectively asking the market to underwrite a weak near-term bridge in exchange for a more credible multi-quarter reset, and that usually matters more for a deeply de-rated industrial than an isolated beat. When a stock is already trading near the low end of implied value, the upside comes less from estimates moving up immediately and more from the market deciding the turnaround has stopped getting worse.

Second-order, the mix matters: evidence of share gains in one crop-protection line plus firmer Latin America ordering suggests the company may be exiting the worst part of the destocking cycle before peers do. That creates a window where channel restocking, not end-demand, can drive a sharper-than-expected margin inflection over the next 2-3 quarters. The risk is that price declines remain sticky while volume recovery lags, which would keep earnings power capped and make the name a value trap rather than a recovery story.

The guidance reset also likely pressures the entire agricultural inputs complex in the short term, because investors will extrapolate a slower normalization path for distributors and adjacent chemistries. But if FMC is genuinely taking share in a few key products, the loser is not just pricing power at FMC’s competitors; it is the assumption that all ag-chem rebound trades are synchronized. That argues for being selective rather than buying the whole basket.

Contrarian angle: consensus may be over-penalizing the quarter and underpricing the option value of a real operational inflection into late 2026. The market is focused on the next 90 days of disappointment, while the setup likely plays out over 6-12 months as volumes stabilize, inventory burns off, and fixed-cost leverage reappears. If that sequence holds, the stock can re-rate before the earnings model fully catches up.

Key Decisions for Investors

• Go long FMC on a 3-6 month horizon with a starter position now; use the post-earnings reset to build, targeting a 20-30% rerating if the market begins to discount a 2H26 inflection. Risk: if Q2 proves the start of a longer volume air pocket, downside is another 15-20%.
• Buy FMC Jan-2027 calls or call spreads rather than common stock to express the turnaround, since the real catalyst is a multi-quarter margin inflection and the near-term guidance reset should keep implied volatility elevated.
• Pair trade: long FMC / short a higher-multiple ag-chem peer with less visible share gains or weaker regional mix, to isolate execution alpha from sector beta. This works best if the group de-rates on broad guidance caution over the next 1-2 months.
• Avoid chasing the broader agro-inputs basket into this print; the article argues for idiosyncratic winners only. A selective long in FMC is cleaner than a sector-wide long because the second-order benefit from a share shift is not evenly distributed.